Login Register Cart 0
Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Rheumatic Manifestations of Parkinson’s Disease: An Overview

Author(s): Maroua Slouma, Haifa Hajji, Safa Rahmouni*, Rim Dhahri, Leila Metoui and Imen Gharsallah

Volume 19, Issue 3, 2023

Published on: 14 March, 2023

Page: [294 - 302] Pages: 9

DOI: 10.2174/1573397119666230210162808

Price: $65

Abstract

Objectives: Parkinson's disease is the second most common neurodegenerative disorder after Alzheimer's disease. It can be responsible for several rheumatological manifestations.

Aims: This article aimed to review and summarize current knowledge on musculoskeletal diseases associated with Parkinson's disease and their management.

Methods: We conducted a narrative review of musculoskeletal features associated with Parkinson's disease.

Results: Rheumatological manifestations of Parkinson's disease include postural disorders (antecollis, cervical kyphosis, cervical positive sagittal malalignment, camptocormia, Pisa syndrome, scoliosis), bone disorders (osteoporosis, bone fractures), and joint disorders (frozen shoulder, hand, and foot deformities). Rheumatological manifestations lead to physical disability, long-term pain, and impaired quality of life. However, the management of these manifestations is not yet codified. It can associate botulinum toxin, thoraco-pelvic anterior distraction, orthosis, orthopedic surgical correction, pallidotomy, or deep brain stimulation in patients with camptocormia. Therapeutic management of osteoporosis includes calcium and vitamin D intake and bisphosphonates.

Conclusion: Rheumatological manifestations are common in Parkinson’s disease. Optimal care of patients with Parkinson’s disease should include attention to management of postural, bone, and joint disorders since it remains a major cause of functional impairment and disability.

« Previous Next »
Graphical Abstract

[1]
Twelves D, Perkins KSM, Counsell C. Systematic review of incidence studies of Parkinson’s disease. Mov Disord 2003; 18(1): 19-31.
[http://dx.doi.org/10.1002/mds.10305] [PMID: 12518297]
[2]
Simon DK, Tanner CM, Brundin P. Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clin Geriatr Med 2020; 36(1): 1-12.
[http://dx.doi.org/10.1016/j.cger.2019.08.002] [PMID: 31733690]
[3]
Moon BJ, Smith JS, Ames CP, et al. Prevalence and type of cervical deformities among adults with Parkinson’s disease: a cross-sectional study. J Neurosurg Spine 2016; 24(4): 527-34.
[http://dx.doi.org/10.3171/2015.6.SPINE141197] [PMID: 26654338]
[4]
Armstrong MJ, Okun MS. Diagnosis and treatment of parkinson disease. JAMA 2020; 323(6): 548-60.
[http://dx.doi.org/10.1001/jama.2019.22360] [PMID: 32044947]
[5]
Alwardat M, Schirinzi T, Di Lazzaro G, et al. The influence of postural deformities on neck function and pain in patients with Parkinson’s disease. NeuroRehabilitation 2019; 44(1): 79-84.
[http://dx.doi.org/10.3233/NRE-182505] [PMID: 30741700]
[6]
Ames CP, Blondel B, Scheer JK, et al. Cervical radiographical alignment: comprehensive assessment techniques and potential importance in cervical myelopathy. Spine 2013; 38(22) (Suppl. 1): S149-60.
[http://dx.doi.org/10.1097/BRS.0b013e3182a7f449] [PMID: 24113358]
[7]
Tang JA, Scheer JK, Smith JS, et al. The impact of standing regional cervical sagittal alignment on outcomes in posterior cervical fusion surgery. Neurosurgery 2012; 71(3): 662-9.
[http://dx.doi.org/10.1227/NEU.0b013e31826100c9] [PMID: 22653395]
[8]
Umapathi T, Chaudhry V, Cornblath D, Drachman D, Griffin J, Kuncl R. Head drop and camptocormia. J Neurol Neurosurg Psychiatry 2002; 73(1): 1-7.
[http://dx.doi.org/10.1136/jnnp.73.1.1] [PMID: 12082035]
[9]
Doherty KM, van de Warrenburg BP, Peralta MC, et al. Postural deformities in Parkinson’s disease. Lancet Neurol 2011; 10(6): 538-49.
[http://dx.doi.org/10.1016/S1474-4422(11)70067-9] [PMID: 21514890]
[10]
Bertram KL, Stirpe P, Colosimo C. Treatment of camptocormia with botulinum toxin. Toxicon 2015; 107(Pt A): 148-53.
[http://dx.doi.org/10.1016/j.toxicon.2015.06.004]
[11]
Kashihara K. Postural disorders in Parkinson’s disease: clinical characteristics, frequency, pathophysiology and management. Neurodegener Dis Manag 2012; 2(6): 577-88.
[http://dx.doi.org/10.2217/nmt.12.69]
[12]
Ruttiman R, Eltorai AEM, Daniels AH. Etiology and management of spinal deformity in patients with Parkinson’s Disease. Int J Spine Surg 2018; 12(1): 15-21.
[http://dx.doi.org/10.14444/5003] [PMID: 30280078]
[13]
Fasano A, Geroin C, Berardelli A, et al. Diagnostic criteria for camptocormia in Parkinson’s disease: A consensus-based proposal. Parkinsonism Relat Disord 2018; 53: 53-7.
[http://dx.doi.org/10.1016/j.parkreldis.2018.04.033] [PMID: 29759930]
[14]
Margraf NG, Rohr A, Granert O, Hampel J, Drews A, Deuschl G. MRI of lumbar trunk muscles in patients with Parkinson’s disease and camptocormia. J Neurol 2015; 262(7): 1655-64.
[http://dx.doi.org/10.1007/s00415-015-7726-3] [PMID: 25929656]
[15]
Lepoutre A-C, Devos D, Blanchard-Dauphin A, et al. A specific clinical pattern of camptocormia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2006; 77(11): 1229-34.
[http://dx.doi.org/10.1136/jnnp.2005.083998] [PMID: 16735399]
[16]
Arii Y, Sawada Y, Kawamura K, et al. Immediate effect of spinal magnetic stimulation on camptocormia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2014; 85(11): 1221-6.
[http://dx.doi.org/10.1136/jnnp-2014-307651] [PMID: 24780955]
[17]
Tiple D, Fabbrini G, Colosimo C, et al. Camptocormia in Parkinson disease: an epidemiological and clinical study. J Neurol Neurosurg Psychiatry 2009; 80(2): 145-8.
[http://dx.doi.org/10.1136/jnnp.2008.150011] [PMID: 18931011]
[18]
Bloch F, Houeto JL, Tezenas du Montcel S, et al. Parkinson’s disease with camptocormia. J Neurol Neurosurg Psychiatry 2006; 77(11): 1223-8.
[http://dx.doi.org/10.1136/jnnp.2006.087908] [PMID: 16754693]
[19]
Ou R, Liu H, Hou Y, et al. Predictors of camptocormia in patients with Parkinson’s disease: A prospective study from southwest China. Parkinsonism Relat Disord 2018; 52: 69-75.
[http://dx.doi.org/10.1016/j.parkreldis.2018.03.020] [PMID: 29606604]
[20]
Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17(5): 427-42.
[http://dx.doi.org/10.1212/WNL.17.5.427] [PMID: 6067254]
[21]
Srivanitchapoom P, Hallett M. Camptocormia in Parkinson’s disease: definition, epidemiology, pathogenesis and treatment modalities. J Neurol Neurosurg Psychiatry 2016; 87(1): 75-85.
[PMID: 25896683]
[22]
Magrinelli F, Geroin C, Squintani G, et al. Upper camptocormia in Parkinson’s disease: Neurophysiological and imaging findings of both central and peripheral pathophysiological mechanisms. Parkinsonism Relat Disord 2020; 71: 28-34.
[http://dx.doi.org/10.1016/j.parkreldis.2020.01.004] [PMID: 31981996]
[23]
Margraf NG, Wrede A, Deuschl G, Schulz-Schaeffer WJ. Pathophysiological concepts and treatment of camptocormia. J Parkinsons Dis 2016; 6(3): 485-501.
[http://dx.doi.org/10.3233/JPD-160836] [PMID: 27314757]
[24]
Mills R, Bahroo L, Pagan F. An update on the use of botulinum toxin therapy in Parkinson’s disease. Curr Neurol Neurosci Rep 2015; 15(1): 511.
[http://dx.doi.org/10.1007/s11910-014-0511-3] [PMID: 25407133]
[25]
Furusawa Y, Mukai Y, Kobayashi Y, Sakamoto T, Murata M. Role of the external oblique muscle in upper camptocormia for patients with Parkinson’s disease. Mov Disord 2012; 27(6): 802-3.
[http://dx.doi.org/10.1002/mds.24930] [PMID: 22290442]
[26]
Sèze M, Creuzé A, Sèze M, Mazaux J. An orthosis and physiotherapy programme for camptocormia: A prospective case study. J Rehabil Med 2008; 40(9): 761-5.
[http://dx.doi.org/10.2340/16501977-0252] [PMID: 18843430]
[27]
Ye X, Lou D, Ding X, et al. A clinical study of the coronal plane deformity in Parkinson disease. Eur Spine J 2017; 26(7): 1862-70.
[http://dx.doi.org/10.1007/s00586-017-5018-6] [PMID: 28281005]
[28]
Galbusera F, Bassani T, Stucovitz E, et al. Surgical treatment of spinal disorders in Parkinson’s disease. Eur Spine J 2018; 27(S1) (Suppl. 1): 101-8.
[http://dx.doi.org/10.1007/s00586-018-5499-y] [PMID: 29397444]
[29]
Capelle HH, Schrader C, Blahak C, et al. Deep brain stimulation for camptocormia in dystonia and Parkinson’s disease. J Neurol 2011; 258(1): 96-103.
[http://dx.doi.org/10.1007/s00415-010-5695-0] [PMID: 20803027]
[30]
Yamada K, Shinojima N, Hamasaki T, Kuratsu J. Subthalamic nucleus stimulation improves Parkinson’s disease-associated camptocormia in parallel to its preoperative levodopa responsiveness. J Neurol Neurosurg Psychiatry 2016; 87(7): 703-9.
[http://dx.doi.org/10.1136/jnnp-2015-310926] [PMID: 26424897]
[31]
Schulz-Schaeffer Walter J, Margraf Nils G, Munser Sari, et al. Effect of neurostimulation on camptocormia in Parkinson’s disease depends on symptom duration. Mov Disord 2015; 30(3): 368-72.
[32]
Ashour R, Jankovic J. Joint and skeletal deformities in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Mov Disord 2006; 21(11): 1856-63.
[http://dx.doi.org/10.1002/mds.21058] [PMID: 16941460]
[33]
Canning CG, Paul SS, Nieuwboer A. Prevention of falls in Parkinson’s disease: a review of fall risk factors and the role of physical interventions. Neurodegener Dis Manag 2014; 4(3): 203-21.
[http://dx.doi.org/10.2217/nmt.14.22] [PMID: 25095816]
[34]
Duvoisin RC, Marsden CD. Note on the scoliosis of Parkinsonism. J Neurol Neurosurg Psychiatry 1975; 38(8): 787-93.
[http://dx.doi.org/10.1136/jnnp.38.8.787] [PMID: 1185199]
[35]
Tinazzi M, Fasano A, Geroin C, et al. Pisa syndrome in Parkinson disease. Neurology 2015; 85(20): 1769-79.
[http://dx.doi.org/10.1212/WNL.0000000000002122] [PMID: 26491088]
[36]
Castrioto A, Piscicelli C, Pérennou D, Krack P, Debû B. The pathogenesis of Pisa syndrome in Parkinson’s disease. Mov Disord 2014; 29(9): 1100-7.
[http://dx.doi.org/10.1002/mds.25925] [PMID: 24909134]
[37]
Ha Y, Oh JK, Smith JS, et al. Impact of movement disorders on management of spinal deformity in the elderly. Neurosurgery 2015; 77 (Suppl. 1): S173-85.
[http://dx.doi.org/10.1227/NEU.0000000000000940] [PMID: 26378355]
[38]
Bonanni L, Thomas A, Varanese S, Scorrano V, Onofrj M. Botulinum toxin treatment of lateral axial dystonia in parkinsonism. Mov Disord 2007; 22(14): 2097-103.
[http://dx.doi.org/10.1002/mds.21694] [PMID: 17685467]
[39]
Umemura A, Oka Y, Ohkita K, Yamawaki T, Yamada K. Effect of subthalamic deep brain stimulation on postural abnormality in Parkinson disease. J Neurosurg 2010; 112(6): 1283-8.
[http://dx.doi.org/10.3171/2009.10.JNS09917] [PMID: 19895200]
[40]
Baik JS, Kim JY, Park JH, Han SW, Park JH, Lee MS. Scoliosis in patients with Parkinson’s disease. J Clin Neurol 2009; 5(2): 91-4.
[http://dx.doi.org/10.3988/jcn.2009.5.2.91] [PMID: 19587816]
[41]
Choi HJ, Smith JS, Shaffrey CI, et al. Coronal plane spinal malalignment and Parkinson’s disease: prevalence and associations with disease severity. Spine J 2015; 15(1): 115-21.
[http://dx.doi.org/10.1016/j.spinee.2014.07.004] [PMID: 25041726]
[42]
Klineberg E, Schwab F, Smith JS, Gupta MC, Lafage V, Bess S. Sagittal spinal pelvic alignment. Neurosurg Clin N Am 2013; 24(2): 157-62.
[http://dx.doi.org/10.1016/j.nec.2012.12.003] [PMID: 23561554]
[43]
Bissolotti L, Gobbo M, Villafañe JH, Negrini S. Spinopelvic balance: New biomechanical insights with clinical implications for Parkinson’s disease. European Spine Journal 2014; 23(3): 576-83.
[44]
Oh JK, Smith JS, Shaffrey CI, et al. Sagittal spinopelvic malalignment in Parkinson disease: prevalence and associations with disease severity. Spine 2014; 39(14): E833-41.
[http://dx.doi.org/10.1097/BRS.0000000000000366] [PMID: 24732854]
[45]
Schwab F, Ungar B, Blondel B, et al. Scoliosis Research Society-Schwab adult spinal deformity classification: a validation study. Spine 2012; 37(12): 1077-82.
[http://dx.doi.org/10.1097/BRS.0b013e31823e15e2] [PMID: 22045006]
[46]
Schwab FJ, Blondel B, Bess S, et al. Radiographical spinopelvic parameters and disability in the setting of adult spinal deformity: a prospective multicenter analysis. Spine 2013; 38(13): E803-12.
[http://dx.doi.org/10.1097/BRS.0b013e318292b7b9] [PMID: 23722572]
[47]
Bezza A, Ouzzif Z, Naji H, et al. Prevalence and risk factors of osteoporosis in patients with Parkinson’s disease. Rheumatol Int 2008; 28(12): 1205-9.
[http://dx.doi.org/10.1007/s00296-008-0632-6] [PMID: 18592245]
[48]
Rimmelzwaan LM, van Schoor NM, Lips P, Berendse HW, Eekhoff EMW. Systematic review of the relationship between vitamin D and Parkinson’s disease. J Parkinsons Dis 2016; 6(1): 29-37.
[http://dx.doi.org/10.3233/JPD-150615] [PMID: 26756741]
[49]
Guo G, Xu S, Cao LD, Wu QY. The effect of levodopa benserazide hydrochloride on homocysteinemia levels in patients with Parkinson’s disease and treatment of hyperhomocysteinemia. Eur Rev Med Pharmacol Sci 2016; 20(11): 2409-12.
[PMID: 27338068]
[50]
Gnädinger M, Mellinghoff HU, Kaelin-Lang A. Parkinson’s disease and the bones. Swiss Med Wkly 2011; 141: w13154.
[PMID: 21328097]
[51]
Invernizzi M, Carda S, Viscontini GS, Cisari C. Osteoporosis in Parkinson’s disease. Parkinsonism Relat Disord 2009; 15(5): 339-46.
[http://dx.doi.org/10.1016/j.parkreldis.2009.02.009] [PMID: 19346153]
[52]
Torsney KM, Noyce AJ, Doherty KM, Bestwick JP, Dobson R, Lees AJ. Bone health in Parkinson’s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2014; 85(10): 1159-66.
[http://dx.doi.org/10.1136/jnnp-2013-307307] [PMID: 24620034]
[53]
Lee SH, Kim MJ, Kim BJ, et al. Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson’s disease. Mov Disord 2010; 25(3): 332-40.
[http://dx.doi.org/10.1002/mds.22866] [PMID: 19938151]
[54]
Malochet-Guinamand S, Durif F, Thomas T. Parkinson’s disease: A risk factor for osteoporosis. Joint Bone Spine 2015; 82(6): 406-10.
[http://dx.doi.org/10.1016/j.jbspin.2015.03.009] [PMID: 26453100]
[55]
Tanner CM, Cummings SR, Schwarzschild MA, et al. The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism. npj. Parkinsons Dis 2021; 7(1): 1-6.
[56]
Henderson EJ, Lyell V, Bhimjiyani A, Amin J, Kobylecki C, Gregson CL. Management of fracture risk in Parkinson’s: A revised algorithm and focused review of treatments. Parkinsonism Relat Disord 2019; 64: 181-7.
[http://dx.doi.org/10.1016/j.parkreldis.2019.03.021] [PMID: 30992234]
[57]
Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008; 19(4): 385-97.
[http://dx.doi.org/10.1007/s00198-007-0543-5] [PMID: 18292978]
[58]
Dennison EM, Compston JE, Flahive J, et al. Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone 2012; 50(6): 1288-93.
[http://dx.doi.org/10.1016/j.bone.2012.02.639] [PMID: 22426498]
[59]
Louvois M, Ferrero S, Barnetche T, Roux CH, Breuil V. High risk of osteoporotic fracture in Parkinson’s disease: Meta-analysis, pathophysiology and management. Rev Neurol (Paris) 2021; 177(6): 660-9.
[http://dx.doi.org/10.1016/j.neurol.2020.07.015] [PMID: 33019997]
[60]
Schini M, Vilaca T, Poku E, et al. The risk of hip and non-vertebral fractures in patients with Parkinson’s disease and parkinsonism: A systematic review and meta-analysis. Bone 2020; 132: 115173.
[http://dx.doi.org/10.1016/j.bone.2019.115173] [PMID: 31790846]
[61]
Allen NE, Schwarzel AK, Canning CG. Recurrent falls in Parkinson’s disease: a systematic review. Parkinsons Dis 2013; 2013: 1-16.
[http://dx.doi.org/10.1155/2013/906274] [PMID: 23533953]
[62]
Roller WC, Glatt S, Vetere-Overfield B, Hassanein R. Falls and Parkinson’s disease. Clin Neuropharmacol 1989; 12(2): 98-105.
[http://dx.doi.org/10.1097/00002826-198904000-00003] [PMID: 2720700]
[63]
Paul SS, Sherrington C, Canning CG, Fung VSC, Close JCT, Lord SR. The relative contribution of physical and cognitive fall risk factors in people with Parkinson’s disease: a large prospective cohort study. Neurorehabil Neural Repair 2014; 28(3): 282-90.
[http://dx.doi.org/10.1177/1545968313508470] [PMID: 24243915]
[64]
Rudzińska M, Bukowczan S, Stożek J, et al. Causes and consequences of falls in Parkinson disease patients in a prospective study. Neurol Neurochir Pol 2013; 47(5): 423-30.
[http://dx.doi.org/10.5114/ninp.2013.38222] [PMID: 24166563]
[65]
Fasano A, Canning CG, Hausdorff JM, Lord S, Rochester L. Falls in Parkinson’s disease: A complex and evolving picture. Mov Disord 2017; 32(11): 1524-36.
[http://dx.doi.org/10.1002/mds.27195] [PMID: 29067726]
[66]
Kendler DL, Bauer DC, Davison KS, et al. Vertebral fractures: clinical importance and management. Am J Med 2016; 129(2): 221.e1-221.e10.
[http://dx.doi.org/10.1016/j.amjmed.2015.09.020] [PMID: 26524708]
[67]
Lyell V, Henderson E, Devine M, Gregson C. Assessment and management of fracture risk in patients with Parkinson’s disease. Age Ageing 2015; 44(1): 34-41.
[http://dx.doi.org/10.1093/ageing/afu122] [PMID: 25236847]
[68]
Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: A consensus update. Mov Disord 2013; 28(7): 863-73.
[http://dx.doi.org/10.1002/mds.25475] [PMID: 23649720]
[69]
Wijemanne S, Jankovic J. Hand, foot, and spine deformities in parkinsonian disorders. J Neural Transm (Vienna) 2019; 126(3): 253-64.
[http://dx.doi.org/10.1007/s00702-019-01986-1] [PMID: 30809710]
[70]
Gortvai P. Deformities of the hands and feet in Parkinsonism and their reversibility by operation. J Neurol Neurosurg Psychiatry 1963; 26(1): 33-6.
[http://dx.doi.org/10.1136/jnnp.26.1.33] [PMID: 13949359]
[71]
Cordivari C, Misra VP, Catania S, Lees AJ. Treatment of dystonic clenched fist with botulinum toxin. Mov Disord 2001; 16(5): 907-13.
[http://dx.doi.org/10.1002/mds.1186] [PMID: 11746621]
[72]
Heinzelmann PR, Dow RW. Clawhand deformity presumed secondary to Parkinson’s disease. J Hand Surg Am 1985; 10(1): 19-21.
[http://dx.doi.org/10.1016/S0363-5023(85)80242-2] [PMID: 3968400]
[73]
Riley D, Lang AE, Blair RD, Birnbaum A, Reid B. Frozen shoulder and other shoulder disturbances in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1989; 52(1): 63-6.
[http://dx.doi.org/10.1136/jnnp.52.1.63] [PMID: 2709037]
[74]
Rana AQ, Khara M, Wasim M, Dogar T, Alenazi B, Qa’aty N. Screening for adhesive capsulitis in the timely diagnosis of Parkinson’s disease. Can J Neurol Sci 2013; 40(1): 123-5.
[http://dx.doi.org/10.1017/S031716710001310X] [PMID: 23250143]
[75]
Papalia R, Torre G, Papalia G, et al. Frozen shoulder or shoulder stiffness from Parkinson disease? Musculoskelet Surg 2019; 103(2): 115-9.
[http://dx.doi.org/10.1007/s12306-018-0567-3] [PMID: 30276531]
[76]
Koh SB, Roh JH, Kim JH, et al. Ultrasonographic findings of shoulder disorders in patients with Parkinson’s disease. Mov Disord 2008; 23(12): 1772-6.
[http://dx.doi.org/10.1002/mds.22191] [PMID: 18661565]
[77]
Yucel A, Kusbeci OY. Magnetic resonance imaging findings of shoulders in Parkinson’s disease. Mov Disord 2010; 25(15): 2524-30.
[http://dx.doi.org/10.1002/mds.23310] [PMID: 20818664]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy